Tweaking host immune responses for novel therapeutic approaches against Mycobacterium tuberculosis
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference110 articles.
1. Global Tuberculosis Report 2021;WHO,2021
2. Novel 6-month treatment for drug-resistant tuberculosis, United States;Haley;Emerg Infect Dis,2021
3. WHO Consolidated guidelines on tuberculosis;WHO,2022
4. Towards a new combination therapy for tuberculosis with next generation benzothiazinones;Makarov;EMBO Mol Med,2014
5. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis;Pethe;Nat Med,2013
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. P-glycoprotein inhibitors as an adjunct therapy for TB;Drug Discovery Today;2024-09
2. 4-(Benzyloxy)phenol-induced p53 exhibits antimycobacterial response triggering phagosome-lysosome fusion through ROS-dependent intracellular Ca2+ pathway in THP-1 cells;Microbiological Research;2024-05
3. TRIM27 elicits protective immunity against tuberculosis by activating TFEB-mediated autophagy flux;Autophagy;2024-03-04
4. Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting Mycobacterium tuberculosis type II NADH dehydrogenase;RSC Medicinal Chemistry;2024
5. Advanced drug delivery and therapeutic strategies for tuberculosis treatment;Journal of Nanobiotechnology;2023-11-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3